IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Hengrui Pharma 01276.HK	Pharmaceuticals	41.45-44.05	200	8,899	2025/05/20	2025/05/22	2025/05/23
Mirxes-B 02629.HK	Biotechnology - Pharmaceuticals	23.3	100	N/A	2025/05/20	2025/05/22	2025/05/23
PegBio Co-B 02565.HK	Biotechnology - Pharmaceuticals	15.6	500	N/A	2025/05/22	2025/05/26	2025/05/27
Jihong Company 02603.HK	Paper Products	7.48-10.68	500	5,394	2025/05/22	2025/05/26	2025/05/27

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Hengrui Pharma
01276.HK

Pharmaceuticals

41.45-44.05

200

8,899

2025/05/20

2025/05/22

2025/05/23

Mirxes-B
02629.HK

Biotechnology - Pharmaceuticals

23.3

100

N/A

2025/05/20

2025/05/22

2025/05/23

PegBio Co-B
02565.HK

Biotechnology - Pharmaceuticals

15.6

500

N/A

2025/05/22

2025/05/26

2025/05/27

Jihong Company
02603.HK

Paper Products

7.48-10.68

500

5,394

2025/05/22

2025/05/26

2025/05/27

Summary

Founded in 2008, we are a biotechnology company focused on the in-house discovery and development of innovative therapies, primarily peptide and small molecule drugs, for chronic diseases with a particular emphasis on metabolic disorders. We have self-developed one Core Product and other five product candidates to capture the market potential in prevalent chronic and metabolic diseases, including type 2 diabetes mellitus (“T2DM”, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (“NASH”), opioid-induced constipation (“OIC”, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia). Our Core Product, PB-119, is a self-developed, near-commercialized, long-acting glucagon- like peptide (“GLP-1”, a peptide hormone that decreases blood sugar levels) receptor agonist. GLP-1 receptor agonist is an agent that activates the GLP-1 receptor to simulate the receptor activation functions of GLP-1, which primarily include insulin secretion promotion, glucagon secretion inhibition, suppressing gastric motility and appetite, glucose uptake and fat degradation. PB-119 is primarily designed for the first-line treatment of T2DM and obesity. It has demonstrated multiple benefits in glycemic control, cardiovascular health, and a good efficacy profile in weight management across several clinical trials. According to CIC, long-acting GLP-1 receptor agonists referred to products that require an once-weekly dosing schedule such as that of PB-119, as compared to the frequent once- or multiple-daily dosing schedule required by short-acting GLP-1 receptor agonists. The new drug application (“NDA”) for PB-119 in China for T2DM was accepted by the NMPA in September 2023, marking a key milestone for its upcoming commercialization. WE MAY NOT BE ABLE TO SUCCESSFULLY DEVELOP AND/OR MARKET OUR CORE PRODUCT. We are developing our Core Product and other product candidates in highly competitive markets with intense competition from multi-national and domestic pharmaceutical companies with multiple approved drugs and similar drug candidates at similar or more advanced clinical stages. For more details, see “Risk Factors — We may face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our drug candidates.” Our Business Model Our core business model is to discover and develop in-house innovative therapies for chronic diseases to address medical needs. All drug candidates listed in the above chart are developed by us. To complement our internal efforts, we may seek collaborative opportunities on the clinical development and commercialization of our drug candidates to better capture market opportunities through out-licensing, co-commercialization or other strategic collaborations. Source: PegBio Co-B (02565) Prospectus (IPO Date : 2025/05/19)
Listing Market	MAIN
Industry	Biotechnology - Pharmaceuticals
Background	H Shares
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Michael Min XU (22.61%) Mingly China Growth Fund, L.P. (9.03%)
Directors	Michael Min XU (Chairman and General Manager and Executive Director) Xiaojun WANG (Chief Financial Officer and Executive Director) Hongkai LI (Non-Executive Director) Ting ZHAI (Non-Executive Director) Xiangjun ZHOU (Non-Executive Director) Yuhong XU (Non-Executive Director) Jiancun ZHANG (Independent Non-Executive Director) Xinpeng FAN (Independent Non-Executive Director) Yangyang CHEN (Independent Non-Executive Director)
Company Secretary	Yifeng HUANG Yuen Mui CHAN
Principal Bankers	China Construction Bank
Solicitors	JunHe LLP Davis Polk & Wardwell
Auditors	KPMG
Registered Office	46/F, Hopewell Centre., 183 Queen’s Road East, Wanchai, Hong Kong
Share Registrars	Computershare Hong Kong Investor Services Ltd. [Tel: (852) 2862-8628]
Share Registrars Tel No	(852) 2862-8628
Internet Address	http://www.pegbio.com
Email Address
Tel No
Fax No

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates